Current Opinion in Nephrology and Hypertension was launched in 1992. It is part of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of nephrology and hypertension is divided into 12 sections that are each reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue.
Dr Jonathan Himmelfarb graduated from George Washington University School of Medicine, USA, and completed the internship and medical residency at the Maine Medical Center, USA. After finishing his nephrology fellowship at Brigham and Women's Hospital in Boston, USA in 1998, he continued his career at the Maine Medical Center, in the Division of Nephrology and Transplantation.
In 1997, Dr Himmelfarb was appointed the Director of the Division of Nephrology and Transplantation at the Maine Medical Center, where he also became the Associate Chair for Research, in the Department of Medicine. He served as Director of Clinical and Translational Research at the Maine Medical Center Research Institute, USA. Since 2008, Dr Himmelfarb is Director of the Kidney Research Institute, Professor of Medicine, and holds the Joseph W. Eschbach M.D. Endowed Chair in Kidney Research, at the University of Washington, USA.
Dr Himmelfarb has served on numerous study sections and grant review committees, Scientific Advisory Boards and held leadership positions in many national and international nephrology societies. He has been a member of the American Board of Internal Medicine Subspecialty Board on Nephrology. Dr Himmelfarb has served on the editorial boards of the Journal of the American Society of Nephrology (JASN), Clinical Journal of the American Society of Nephrology (CJASN), Kidney International, and BMC Medicine. He is also currently North American Editor for Dialysis and Renal Transplantation, for the Faculty of 1000 in medicine.
Dr Himmelfarb is the author of more than 160 peer-reviewed publications, including original research, reviews, and editorials. His current research interests include: development and evaluation of risk biomarkers in acute and chronic kidney disease; studies of oxidative stress, inflammation and insulin resistance in kidney disease; performance of randomized clinical trials as part of several NIH Consortia, as well as numerous investigator-initiated clinical trials and cohort studies.
Dr Roy Bloom received his medical degree from the University of Witwatersrand in Johannesburg, South Africa. After completing an internship at the Johannesburg Hospital, South Africa, he did postgraduate training in London, UK. Here he served as a Senior House Officer at Guy's Hospital, Hammersmith Hospital and the Royal Free Hospital, UK. He subsequently completed a medical residency at Albert Einstein Medical Center in Philadelphia, USA. This was followed by nephrology fellowships. These were at Brigham and Women's Hospital in Boston, USA and the Hospital of the University of Pennsylvania in Philadelphia, USA, completed in 1994.
Dr Bloom later joined the Division of Nephrology at Albert Einstein Medical Center where he was appointed Medical Director of the Kidney Transplant Program. From 1997 to 1998, he served as Medical Director of the Kidney Transplant Program at Allegheny University of the Health Sciences/Hahnemann Hospital in Philadelphia, USA. Since 1999, he has been a faculty member of the Renal Electrolyte and Hypertension Division at the University of Pennsylvania, USA, where he is now a Professor of Medicine. He has been the Medical Director of the Penn Transplant Institute Kidney and Pancreas Transplant Programs since 2002.
Dr Bloom is a member of the American Society of Nephrology and the American Society of Transplantation. He has chaired both the Patient Care and Education Committee and the Clinical Trials Advisory Council of the American Society of Transplantation and currently serves on the Education Committee of this society as well. He also serves on the American Society of Nephrology's Postgraduate Education Committee; concomitant with being a member of their Transplant Advisory Group. He has served on KDIGO Work Groups related to the development of clinical practice guidelines for both managing hepatitis C virus in kidney disease, as well as for the management of kidney transplant recipients.
Dr Bloom has served on program committees for the American Transplant Congress and has organized transplant-related symposia, at the American Diabetes Association Annual Meeting. He is the author of over 100 publications, including original research, reviews, editorials and book chapters. In 2005, he received the American Society of Transplantation Wyeth Clinical Science Career Development Award. His current research interests include: issues related to organ allocation and living donation, kidney transplant outcomes related to patient co-morbidities such as hepatitis C infection; studies of complications of solid organ transplantation; performance of clinical trials with contemporary and emerging immunosuppressive therapies.
Dr Maarten Taal graduated from the University of Cape Town Medical School, South Africa, in 1987. After completion of post-graduate training in internal medicine and nephrology, at Groote Schuur Hospital, Cape Town, South Africa, he moved to Brigham and Women's Hospital, Boston, US. His research under the directorship of Dr Barry M. Brenner focused on mechanisms underlying the progression of chronic kidney disease and led to his attainment of a Doctor of Medicine degree. Following on from this, Maarten Taal moved to the United Kingdom where he was appointed a Consultant Renal Physician at Royal Derby Hospital, UK, in 2002; and Honorary Associate Professor at the University of Nottingham Medical School, UK, in 2011. His current research interests include chronic kidney disease progression, diabetic nephropathy; renal osteodystrophy; cardiovascular disease in patients with chronic kidney disease and risk prediction.